DUBLIN and CHICAGO, Oct. 7,
2016 /PRNewswire/ -- Allergan and the Dystonia Medical
Research Foundation (DMRF) are proud to continue their
long-standing partnership in support of dystonia patients by
conducting a survey to evaluate awareness of cervical dystonia, its
symptoms and treatment options in order to encourage education and
proper diagnosis of this often-disabling condition.
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
"Our partnership with Allergan on this survey will support
patients with cervical dystonia and their families by shedding
light on the lack of awareness of the condition," said Art Kessler, DMRF President. "It is imperative
that patients have accurate information about cervical dystonia in
order to seek the appropriate care and treatment options. Equally
as critical, is continuing to work with a healthcare provider."
Dystonia is a chronic movement disorder that is estimated to
affect as many as 250,000 people in the
United States, making it the third most common movement
disorder behind essential tremor and Parkinson's disease. It is
identified by involuntary muscle contractions that cause repetitive
movements and abnormal postures of the body and limbs. There are
numerous subtypes that affect people of all ages and backgrounds,
including cervical dystonia. Common symptoms of cervical dystonia
include abnormal head position and neck pain. Allergan's
BOTOX® (onabotulinumtoxinA) is a first-line treatment to
treat the abnormal head position and neck pain associated with
cervical dystonia in people 16 years and older.
"Allergan is committed to supporting patients with cervical
dystonia and educating the public about this condition in order to
encourage proper diagnosis and treatment," said Mitchell Brin, M.D., Senior Vice President
Global Drug Development and Chief Scientific Officer,
BOTOX®. "We value our continued partnership with the
DMRF to raise awareness of cervical dystonia, potential treatment
options and the importance of talking to your doctor."
DMRF's partnership with Allergan has also included raising
awareness through Dystonia Zoo Walks in ten cities across
the United States. These community
events bring together patients, healthcare providers and families
and increase visibility of dystonia. To date, 150,000 people have
become more educated on dystonia through these events.
For more information about cervical dystonia, including a tool
to find a specialist, please visit BOTOXcervicaldystonia.com.
Indication
BOTOX® is a prescription medicine that is injected into muscles
and used to treat the abnormal head position and neck pain that
happens with cervical dystonia (CD) in people 16 years and
older.
IMPORTANT SAFETY INFORMATION
BOTOX® may cause serious side effects that
can be life threatening. Get medical help right away if you have
any of these problems any time (hours to weeks) after injection of
BOTOX®:
- Problems swallowing, speaking, or breathing, due to
weakening of associated muscles, can be severe and result in loss
of life. You are at the highest risk if these problems are
pre-existing before injection. Swallowing problems may last for
several months.
- Spread of toxin effects. The effect of botulinum
toxin may affect areas away from the injection site and cause
serious symptoms including: loss of strength and all-over muscle
weakness, double vision, blurred vision and drooping eyelids,
hoarseness or change or loss of voice, trouble saying words
clearly, loss of bladder control, trouble breathing, trouble
swallowing.
BOTOX® may cause loss of strength or general
muscle weakness, vision problems, or dizziness within hours to
weeks of taking BOTOX®. If this happens, do not
drive a car, operate machinery, or do other dangerous
activities.
Do not take BOTOX® if you: are
allergic to any of the ingredients in BOTOX® (see
Medication Guide for ingredients); had an allergic reaction to any
other botulinum toxin product such
as Myobloc® (rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA),
or Xeomin® (incobotulinumtoxinA); have
a skin infection at the planned injection site.
The dose of BOTOX® is not the same as, or
comparable to, another botulinum toxin product.
Serious and/or immediate allergic reactions have been
reported. They include itching, rash, red itchy welts,
wheezing, asthma symptoms, or dizziness or feeling faint. Get
medical help right away if you experience symptoms; further
injection of BOTOX® should be discontinued.
Tell your doctor about all your muscle or nerve
conditions such as ALS or Lou
Gehrig's disease, myasthenia gravis, or Lambert-Eaton
syndrome, as you may be at increased risk of serious side effects
including difficulty swallowing and difficulty breathing from
typical doses of BOTOX®.
Tell your doctor about all your medical conditions, including
if you: have or have had bleeding problems; have plans to
have surgery; had surgery on your face; weakness of forehead
muscles; trouble raising your eyebrows; drooping eyelids; any other
abnormal facial change; are pregnant or plan to become pregnant (it
is not known if BOTOX® can harm your unborn baby);
are breastfeeding or plan to (it is not known if
BOTOX® passes into breast milk).
Tell your doctor about all the medicines you
take, including prescription and nonprescription
medicines, vitamins, and herbal products. Using BOTOX®
with certain other medicines may cause serious side
effects. Do not start any new medicines until you have told
your doctor that you have received BOTOX® in the
past.
Tell your doctor if you have received any other botulinum toxin
product in the last 4 months; have received injections of botulinum
toxin such
as Myobloc®,Dysport®,
or Xeomin® in the past (tell your
doctor exactly which product you received); have recently received
an antibiotic by injection; take muscle relaxants; take an allergy
or cold medicine; take a sleep medicine; take aspirin-like products
or blood thinners.
Other side effects of
BOTOX® include: dry mouth, discomfort or
pain at the injection site, tiredness, headache, neck pain, and eye
problems: double vision, blurred vision, decreased eyesight,
drooping eyelids, swelling of your eyelids, and dry eyes.
For more information refer to the Medication Guide or talk with
your doctor.
You are encouraged to report negative side effects of
prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see BOTOX® full Product
Information including Boxed Warning
and Medication Guide.
Myobloc is a registered trademark of Solstice
Neurosciences, Inc.
About the Dystonia Medical Research Foundation
The Dystonia Medical Research Foundation (DMRF) is a 501(c)(3)
non-profit organization dedicated to advancing research for
improved dystonia treatments and ultimately a cure, promoting
awareness and patient education, and supporting the well-being of
affected individuals and families. The DMRF can be reached at
800-377-3978 or www.dystonia-foundation.org.
About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing, manufacturing and
commercializing branded pharmaceuticals, devices and biologic
products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company's
R&D model, which defines our approach to identifying and
developing game-changing ideas and innovation for better patient
care. This approach has led to Allergan building one of the
broadest development pipelines in the pharmaceutical industry with
65+ mid-to-late stage pipeline programs in development.
Our Company\'s success is powered by our more than 15,000 global
colleagues' commitment to being Bold for Life. Together, we build
bridges, power ideas, act fast and drive results for our customers
and patients around the world by always doing what it is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives.
For more information, visit Allergan's website at
www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the difficulty of predicting the timing or
outcome of FDA approvals or actions, if any; the impact of
competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Annual Report
on Form 10-K for the year ended December 31,
2015 and Quarterly Report on Form 10-Q for the quarter ended
March 31, 2016 (certain of such
periodic public filings having been filed under the "Actavis plc"
name). Except as expressly required by law, Allergan disclaims any
intent or obligation to update these forward-looking
statements.
CONTACTS:
DMRF Media:
Jessica Freeley
(912) 510-0337
Allergan Media:
Mark Marmur
(862) 261-7558
Lisa Kim
(714) 246-3843
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-and-the-dystonia-medical-research-foundation-continue-longstanding-partnership-300340873.html
SOURCE Allergan plc